The founder of the Dr. Goodenowe Restorative Health Center, Dayan Goodenowe, has announced plans to establish a drug manufacturing lab and clinical trials center in Moose Jaw, Saskatchewan, aimed at creating an “Alzheimer’s eradication program.” During a presentation on February 13, Goodenowe asserted that he has the knowledge to combat Alzheimer’s, referencing his book, Breaking Alzheimer’s. He promoted his supplement, ProdromeNeuro, as a treatment he believes could gain FDA approval by 2029. Despite past controversies and claims about his work, including a warning from the FDA regarding the safety of a previous study, Goodenowe continues to advocate for his methods and products, asserting they will redefine care standards for Alzheimer’s. His assertions have drawn skepticism from former investors and industry peers regarding their reliability and truthfulness.
Why It Matters
Dayan Goodenowe’s venture into Alzheimer’s treatment underscores the complexities and challenges of drug development, particularly in the field of neurodegenerative diseases. Historical efforts to bring innovative therapies to market have often faced significant hurdles, including regulatory scrutiny and the need for rigorous clinical validation. The FDA’s warning regarding Goodenowe’s previous studies highlights the importance of adhering to established research protocols to ensure participant safety. Furthermore, the ongoing debate around supplements and their efficacy in treating serious illnesses reflects broader concerns in the medical community about the validity of alternative treatments and the need for evidence-based practices.
Want More Context? 🔎
